Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ProQR Therapeutics N.V. (PRQR : NSDQ)

• Company Description    ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. Number of Employees: 166

• Price / Volume Information    Yesterday's Closing Price: $2.22 Daily Weekly Monthly 20 Day Moving Average: 611,488 shares Shares Outstanding: 105.21 (millions) Market Capitalization: $233.57 (millions) Beta: 0.16 52 Week High: $4.21 52 Week Low: $1.07 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.88% -10.30% 12 Week 8.29% 3.80% Year To Date -16.23% -26.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ZERNIKEDREEF 9 - LEIDEN,P7 2333 CK NLD ph: 31-88-166-7000 fax: - ir@proqr.com http://www.proqr.com

• General Corporate Information    Officers Daniel de Boer - Chief Executive Officer Dinko Valerio - chairman Jurriaan Dekkers - Chief Financial Officer Andrew Morris - Vice President Sheila Sponselee - Chief People & Operations Officer Peer Information ProQR Therapeutics N.V. (CORR.) ProQR Therapeutics N.V. (RSPI) ProQR Therapeutics N.V. (CGXP) ProQR Therapeutics N.V. (BGEN) ProQR Therapeutics N.V. (GTBP) ProQR Therapeutics N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N71542109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/12/26 Share - Related Items Shares Outstanding: 105.21 Most Recent Split Date: (:1) Beta: 0.16 Market Capitalization: $233.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.50 Price/Cash Flow: - Price / Sales: 13.52 EPS Growth vs. Year Ago Period: -9.09% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: -20.24% vs. Previous Quarter: -22.21% ROE 09/30/25 - -58.70 06/30/25 - -61.25 03/31/25 - -53.49 ROA 09/30/25 - -29.37 06/30/25 - -28.13 03/31/25 - -22.07 Current Ratio 09/30/25 - 3.36 06/30/25 - 3.76 03/31/25 - 4.10 Quick Ratio 09/30/25 - 3.36 06/30/25 - 3.76 03/31/25 - 4.10 Operating Margin 09/30/25 - -273.20 06/30/25 - -238.52 03/31/25 - -157.04 Net Margin 09/30/25 - -273.20 06/30/25 - -238.52 03/31/25 - -157.04 Pre-Tax Margin 09/30/25 - -273.13 06/30/25 - -238.49 03/31/25 - -158.13 Book Value 09/30/25 - 0.63 06/30/25 - 0.72 03/31/25 - 0.79 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©